Quest Diagnostics
558 hedge funds and large institutions have $10.5B invested in Quest Diagnostics in 2016 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 205 increasing their positions, 197 reducing their positions, and 41 closing their positions.
61% more call options, than puts
Call options by funds: $37.9M | Put options by funds: $23.6M
27% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 41
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
12% more capital invested
Capital invested by funds: $9.39B → $10.5B (+$1.08B)
4% more repeat investments, than reductions
Existing positions increased: 205 | Existing positions reduced: 197
0% more funds holding
Funds holding: 557 → 558 (+1)
1.12% less ownership
Funds ownership: 92.1% → 90.98% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$95.2M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$77.8M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$74.6M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$54.9M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$45.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$229M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$70.2M |
| 3 |
HM
HealthCor Management
New York
|
-$53.3M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$52.8M |
| 5 |
Axa
Paris,
France
|
-$52.2M |
DGX Hedge Fund Activity: Q2 2016 in Review
558 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q2 2016, worth a combined $10.5B — up 12% from $9.39B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new DGX positions and 41 closed out — a net gain of 11 holders — while 205 added to existing stakes and 197 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $95.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $229M.
- 558 institutional investors held Quest Diagnostics (DGX) as of Q2 2016, up from 557 in Q1 2016.
- Funds reported $10.5B of Quest Diagnostics stock for Q2 2016, up 12% quarter-over-quarter.
- 52 funds opened new Quest Diagnostics positions in Q2 2016 and 41 closed out, a net change of +11 holders.
- The largest Quest Diagnostics buyer in Q2 2016 was Victory Capital Management, an estimated $95.2M added.
- The largest Quest Diagnostics seller in Q2 2016 was T. Rowe Price Associates, an estimated $229M sold.
Based on aggregated 13F filings for Q2 2016.